SAVE THE DATE -- Annual Program Symposium featuring Irving W. Wainer (NIH), as the keynote speaker on Tues. April 22, 2014 in E103 Beadle Center. Seminar title: . “When you come to a fork in the road, take it!”*
Methoxynaphthylfenoterol and the biological, chemical and pharmacological journey from congestive heart failure to cancer.
Professor Irving W Wainer is an Adjunct Professor in the Department of Anesthesiology, Cooper Medical School of Rowan University and the Department of Oncology, McGill University. He received his PhD degree in chemistry from Cornell University and did postdoctoral doctoral studies in molecular biology (University of Oregon) and clinical pharmacology (Thomas Jefferson Medical School). He worked for the US Food and Drug Administration as a Research Chemist, St. Jude’s Children's Research Hospital, at McGill University as Professor and Head, Pharmacokinetics Laboratory, Department of Oncology, as Professor of Pharmacology at Georgetown University and until March 31 was a Senior Investigator in the Laboratory of Clinical Investigation at the National Institute on Aging/NIH. Professor Wainer has published over 360 scientific papers, 10 books, 25 book chapters holds 11 patents, and was founding editor of the journal Chirality and Senior Editor of the Journal of Chromatography B. His awards include: the "A.J.P. Martin Medal" presented by the Chromatographic Society; Elected Fellow of the American Academy of Pharmaceutical Sciences; Doctor Honoris Causa awarded by the Medical University of Gdansk, Doctor Honoris Causa awarded by the Department of Medicine, University of Liege, the 2013 Dal Nogare Award presented by the Chromatography Forum of the Delaware Valley and the 2013 Eastern Analytical Symposium Award for Outstanding Contributions to the Fields of Analytical Chemistry. Professor Wainer research includes the study of the effect of disease progression and aging on drug metabolism in critically ill and terminal patients, new tools for drug discovery using cellular membrane affinity chromatography (CMAC), and the development of new therapeutic agents for the treatment of oncologic and cardiovascular diseases and for use in depression and pain therapy.